My clinical interests are the infectious complications of patients with cancer treated in the University of Maryland Greenebaum Cancer Center. Cancer patients may be treated with chemotherapy, immune modulators or bone marrow/stem cell transplantation. The host immune system is impaired to varying degrees depending on the type of malignancy and the way in which it is treated. The most profoundly immunosuppressed cancer patients are frequently infected, often by pathogens that are not virulent to people defended by normal immune systems.
My academic interests are development of methods to optimize treatment of infections in complicated neutropenic patients and in bone marrow/stem cell transplant recipients. The complexity of infection management in these patients defies standard drug/bug models since patients must often be treated empirically for some time before it is possible to make accurate diagnoses. These patients are best treated through algorithm-driven treatment models where treatment choices are reevaluated repeatedly as diagnostic testing data and observations of patients responses are used to refine the initial approaches and to arrive at the best outcomes.
I have a strong interest in quality improvement initiatives in my roles as Director of the University of Maryland Medical Center Antimicrobial Stewardship Program and as chair of the University of Maryland Greenebaum Cancer Center Data Safety Monitoring (DSM) Committee. The goal of antimicrobial stewardship is to optimize diagnosis and treatment of infections in UMMC patients by promoting and monitoring clinical best practices. The goal of the DSM committee is to maximize safety of patients enrolled in clinical trials offered by the Cancer Center.